Disposables Help Drive Operational Excellence in Pharmaceutical and Biotech Manufacturing

Disposables Help Drive Operational Excellence in Pharmaceutical and Biotech Manufacturing 

By Janice Abel and John Blanchard, ARC Advisory Group

Overview

Biotechnology and pharmaceutical manufacturers have been looking for ways to improve operations, changeovers, and quality, and reduce costs.  Depending upon the scale and specifics of the process and the automation requirements - disposable bags and equipment can often improve manufacturing efficiencies and reduce capital costs. 

For these reasons, the industry has seen rapid adoption of single-use or disposable technologies over the past five years - particularly for clinical and smaller scale production applications.  Future applications will also include production of vaccines and personalized medicines.  By improving product quality, increasing efficiencies and yields, and reducing waste - disposable bags and equipment can help improve overall operational excellence, a strategic objective for virtually all of today's biopharm manufacturers.  Just as important, it can also reduce the new facility costs and product time-to-market.

Disposable technologies also present opportunities for automation suppliers to work more closely with OEMs to develop and offer validation-ready templates or protocols and modular equipment control strategies that further simplify and minimize validation time and cost.  Automation suppliers can justify the upfront investment in this joint design effort with the high potential it creates for repeat business or annuity.

ARC clients can view the complete report at Disposables Help Drive Operational Excellence in Pharmaceutical and Biotech Manufacturing

If you would like to buy this report or obtain information about how to become a client, please contact [email protected]     

Posted at 12:00 AM by Steve Clouther | Permalink | Email this Post | Comments (0)

Suggested Articles

Inovio CEO J. Joseph Kim is undeterred by short sellers and other detractors who doubt his company can shuttle a COVID-19 DNA vaccine to market.

Adding entinostat to hormone therapy did not help patients with HR-positive, HER2-negative breast cancer live longer.

The data add to the evidence in support of the IL-6 drug ahead of a FDA decision to approve it in a rare disease served by Alexion’s Soliris.